Get notified when APMD files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, with cash insufficient to fund operations for 12 months.
  • Material Weakness (new) — The company is remediating a material weakness in internal controls over financial reporting related to fiscal years 2025 and 2024.
  • Fda Provided Feedback About the Clinical Meaningfulness (new) — The FDA has questioned whether Oxnimbi's Phase 3 data demonstrate clinically meaningful benefit, which could delay or derail approval.
  • Sole Product Candidate (new) — The company's entire business depends on a single product candidate, Oxnimbi, which has not yet received regulatory approval.
APMD APMD 424B4

Apnimed prices $192M IPO at $16/share; company nets $173.6M for sole OSA drug Oxnimbi

Filed July 31, 2026 · ~1 min read

Key Changes

  • high

    Apnimed is selling 12M shares at $16.00 each, raising $192M gross; after underwriting discounts and expenses, the company nets about $173.6M.

    The Offering verify on EDGAR →
  • high

    The company's sole product candidate, Oxnimbi, is under FDA review with a PDUFA goal date of February 28, 2027; the FDA has questioned the clinical meaningfulness of Phase 3 endpoints.

    Prospectus Summary verify on EDGAR →
  • high

    Apnimed reported a GAAP net loss of $128.2M for 2025, driven by a $67.4M loss from discontinued operations and a $5.6M fair-value loss on convertible notes.

    Management's Discussion and Analysis verify on EDGAR →

3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.

Partner

Trade APMD commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify